ArticleJournal of neuro-oncology2016
The incidence and significance of multicentric noncontrast-enhancing lesions distant from a histologically-proven glioblastoma.
Article in Journal of neuro-oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Multiple high-grade gliomas: epidemiology, management, and outcome. A systematic review and meta-analysis.Neurosurgical review · 2019Pooled it
- Differentiation between Nonenhancing Tumor in Glioblastoma and Vasogenic Edema Using Diffusion-Weighted and Dynamic Susceptibility Contrast MR Imaging.AJNR. American journal of neuroradiology · 2025Article
- Autoimmune Encephalitis-like Presentation of Glioblastoma: Get to Know This Rare Occurrence.Journal of clinical medicine · 2025Article
- Different risk factors for multiple and unifocal gliomas: a comparative study of radiological, pathological and clinical characteristics.Frontiers in oncology · 2025Article
- Atypical induction of HIF-1α expression by pericellular Notch1 signaling suffices for the malignancy of glioblastoma multiforme cells.Cellular and molecular life sciences : CMLS · 2022Article
- Gyriform infiltration as imaging biomarker for molecular glioblastomas.Journal of neuro-oncology · 2022Article
- Multicentric Glioma: An Ideal Model to Reveal the Mechanism of Glioma.Frontiers in oncology · 2022Review
- Genetic Alteration May Proceed with a Histological Change in Glioblastoma: A Report from Initially Diagnosed as Nontumor Lesion Cases.NMC case report journal · 2022Article
- T2/FLAIR Abnormity Could be the Sign of Glioblastoma Dissemination.Frontiers in neurology · 2022Article
- Article
- Decreased CD8Frontiers in oncology · 2021Article
- EGFR gene amplification in monocentric and multicentric glioblastoma.Journal of neuro-oncology · 2019Article
- Non-Contrast-Enhancing Tumor: A New Frontier in Glioblastoma Research.AJNR. American journal of neuroradiology · 2019Review
- Baseline multicentric tumors, distant recurrences and leptomeningeal dissemination predict poor survival in patients with recurrent glioblastomas receiving bevacizumab.Journal of neuro-oncology · 2019Article
- Communicating hydrocephalus and coexisting nonenhancing tumor: An ominous sign for patients with neurofibromatosis type 1?Radiology case reports · 2018Article
- Radiological, clinical, and molecular analyses reveal distinct subtypes of butterfly glioblastomas affecting the prognosis.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Improvements in imaging are increasing the detection of multiple lesions in the setting of glioblastoma. Occasionally distant non-enhancing lesions may be identified which have the appearances of a multicentric low-grade glioma. We aimed to determine the incidence, prognostic significance and diagnostic value of this appearance in new glioblastoma patients. Pre-operative MRIs of patients with a new diagnosis of glioblastoma were reviewed to identify multicentric non-enhancing lesions, defined as areas of FLAIR hyperintensity and mass effect, without post-contrast enhancement, separate from the histologically-proven glioblastoma. Patient survival was compared to glioblastoma patients without these appearances, and follow-up imaging was reviewed. Nine of 151 patients (6 %) had multicentric non-enhancing lesions. Their median survival of 183 days was significantly worse than the 278 days for patients without multicentric nonenhancing lesions (p = 0.025). Follow-up MRIs were performed in four patients. In one patient, there were several additional lesions, one of which developed evidence of necrosis within 22 days of presentation. In the other three patients, the multicentric lesions developed enhancement and evidence of necrosis within 1 year, and became confluent on FLAIR with the dominant lesion. The appearance of a multicentric non-enhancing lesion is an uncommon finding in glioblastoma, but a poor prognostic feature. These lesions progress faster than expected for a low-grade glioma and are thus likely to represent more advanced lesions than their appearances suggest. Confluence with the dominant lesion developing with time suggests that the tumor is more extensive than appreciated on imaging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.